DDIT3 and diffuse large B-cell lymphoma: Responses to treatment conditions in spheroids matched findings from in vivo models, where individual treatments can directly kill DLBCL, however the direct activity of CHOP combined with the immune modulation of rituximab work together to drastically enhance cytotoxicity [15, 46–49].